Virulizin immunomodulator: IMUTF (Toronto) said its planned Phase III trial of Virulizin would not take place until further study, perhaps in a Phase II trial,

IMUTEC Corp. (IMUTF) Product: Virulizin immunomodulator Indication: Pancreatic cancer Status: IMUTF (Toronto) said its planned Phase III trial of Virulizin would not take place until further study, p...